HeartBeam receives FDA Breakthrough Device Designation for at‑home heart‑attack assessment
HeartBeam Inc. (BEAT) was granted FDA Breakthrough Device Designation for its HeartBeam System, a portable 3‑D ECG platform intended to enable clinicians to evaluate possible heart attacks remotely. The designation was based on proof‑of‑concept data from a 134‑patient ALIGN‑ACS pilot study. The news sent the stock sharply higher, with gains of roughly 80% to $0.65 in the week after the announcement. The company also disclosed a $25 million at‑the‑market equity offering and reported Q2 earnings of –$1.10 per share.
Why it matters
The designation speeds regulatory review and opens an expedited Medicare coverage pathway, which could accelerate revenue generation. The equity offering provides up to $25 million of capital to fund the upcoming pivotal study, but may dilute existing shareholders.
Key facts
- 1HeartBeam received FDA Breakthrough Device Designation for its HeartBeam System. rttnews.com
- 2The designation was supported by data from a 134‑patient ALIGN‑ACS pilot study. rttnews.com
- 3BEAT stock closed at $0.43, up 3.72% on October 2, 2026. rttnews.com
- 4In pre‑market trading the stock was at $0.85, up 97.42%. rttnews.com
- 5HeartBeam estimates the heart‑attack assessment market at $15 billion. investing.com
- 6HeartBeam reported Q2 EPS of -$1.10, missing forecasts by $1.01. investing.com
Open questions
- Material 3 cites a broader cardiac platform opportunity of over $40 billion, which differs from the $15 billion heart‑attack assessment market estimate.
- Exact timing for patient enrollment in the planned pivotal study is not disclosed.
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.